Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13036136 | 0.81 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2HDAC4ATMTDP1 | |
| SCHEMBL12932413 | 0.81 | SMN1; SMN2 (0.41) | ALDH1A1SMN1; SMN2HDAC4ATMTDP1 | |
| SCHEMBL9913291 | 0.79 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2HDAC4ATMTDP1 | |
| SCHEMBL13115976 | 0.76 | SMN1; SMN2 (0.39) | ALDH1A1SMN1; SMN2HDAC4ATMTDP1 | |
| SCHEMBL24926263 | 0.73 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2TDP1HTTMEN1 | |
| SCHEMBL13975161 | 0.73 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2TDP1HTTMEN1 | |
| SCHEMBL10312398 | 0.71 | HPGD (0.52) | ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL17373911 | 0.70 | POLB (0.58) | ALDH1A1HDAC4ATMHTTMEN1 | |
| SCHEMBL13211851 | 0.69 | HDAC4 (0.58) | ALDH1A1SMN1; SMN2HDAC4TDP1HTT | |
| SCHEMBL4508029 | 0.69 | POLB (0.56) | ALDH1A1SMN1; SMN2HDAC4ATMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288373-B2 | Modulators of CXCR7 | CHEMOCENTRYX, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20100311712-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100150831-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311712-A1 | MODULATORS OF CXCR7 | CXCR1, CXCR5, CCR7 | ALDH1A1 1777/4885SMN1; SMN2 4503/4885HDAC4 2409/4885 |
| US-20100150831-A1 | MODULATORS OF CXCR7 | CXCR1, CXCR5, CCR7 | ALDH1A1 1777/4885SMN1; SMN2 4503/4885HDAC4 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.